

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/910388
Filing Date	July 20, 2001
First Named Inventor	Kunz, Lawrence
Group Art Unit	1653
Examiner Name	Unknown

RECEIVED  
MAR 12 2003  
TECH CENTER 1600/2900

Sheet 1 of 2

Attorney Docket No: 295.003US5

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
HK	2002/0040064	04/04/2002	Kunz et al.	514	656	07/20/2001
	2002/0086896	07/04/2002	Kunz et al.	514	449	12/18/2001
	2003/0039675	02/27/2003	Kunz et al.	424	423	11/27/2001
	5,175,235	12/29/1992	Domb et al.	528	271	06/04/1990
	5,252,579	10/12/1993	Skotnicki et al.	514	291	02/16/1993
	5,290,271	03/01/1994	Jernberg	604	891.1	07/29/1993
	5,302,584	04/12/1994	Kao et al.	514	80	04/23/1993
	5,362,718	11/08/1994	Skotnicki et al.	514	63	04/18/1994
	5,387,680	02/07/1995	Nelson	540	456	08/10/1993
	5,411,967	05/02/1995	Kao et al.	514	291	04/08/1994
	5,416,205	05/16/1995	della Valle et al.	514	54	11/22/1993
	5,422,362	06/06/1995	Vincent et al.	514	410	07/29/1993
	5,462,966	10/31/1995	Sofia	514	483	10/15/1993
	5,496,581	03/05/1996	Yianni et al.	427	2.12	11/10/1993
	5,504,091	04/02/1996	Molnar-Kimber et al.	514	291	04/14/1994
	5,525,610	06/11/1996	Caufield et al.	514	291	04/26/1995
	5,563,145	10/08/1996	Failli et al.	514	291	12/07/1994
	5,677,295	10/14/1997	Failli et al.	514	183	05/30/1996
	5,981,568	11/09/1999	Kunz et al.	514	411	03/31/1997
	6,171,609	01/09/2001	Kunz	424	422	10/23/1995
	6,306,421	10/23/2001	Kunz et al.	424	423	03/31/1997
	6,358,989	03/19/2002	Kunz et al.	514	411	07/26/1999
	6,491,938	12/10/2002	Kunz et al.	424	423	06/29/2001
V	6,515,009	02/04/2003	Kunz et al.	514	411	02/15/1995

**FOREIGN PATENT DOCUMENTS**

Examiner Initial *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
HK	CA 2,086,642	07/10/1993	Morris et al.	A61K	31/71	
V	EP 0 551 182	07/14/1993	Morris et al.	A61K	31/70	

EXAMINER

*Hope Robinson*

DATE CONSIDERED

1/26/04

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional) ‡ Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449/APTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 2 of 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A(10-01)  
Approved for use through 10/31/2002. OMB 851-0031  
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	09/910388
Filing Date	July 20, 2001
First Named Inventor	Kunz, Lawrence
Group Art Unit	1653
Examiner Name	Unknown

Attorney Docket No: 295.003US5

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>AK</i>		AKSELBAND et al., "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Proliferation of Endothelial Cells and Fibroblasts", <u>Transplantation Proceedings</u> , 23, 2833-2836 (1991).	
		GRAHAM et al., "Dexamethasone Inhibits Growth and Na:H Exchange in Vascular Smooth Muscle Cells", <u>Journal of Endocrinology</u> , 129 (Suppl.), Abstract 180, 10th Joint Meeting of British Endocrine Societies, Brighton, England, UK, April 15-18, 1991.	
		GREGORY et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury", <u>Transplantation</u> , 55, 1409-1418 (1993)	
		MEISER et al., "Effects of Cyclosporin, FK506, and Rapamycin on Graft-Vessel Disease", <u>The Lancet</u> , 338, 1297-1298 (1991).	
		MORRIS et al., "Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic Acid (RS-61443) in Rat and Nonhuman Primate Recipients of Heart Allografts", <u>Transplantation Proceedings</u> , 23, 19-25 (1991).	
		MORRIS, "Rapamycins: Antifungal, Antitumor, Antiproliferative, and Immunosuppressive Macrolides", <u>Transplantation Reviews</u> , 6, 39-87 (1992).	
		NAKANO, "Glucocorticoid Inhibits Thrombin-Induced Expression of Platelet-Derived Growth Factor A-chain and Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells", <u>The Journal of Biological Chemistry</u> , 268, 22941-22947 (1993).	

**RECEIVED**

MAR 12 2003

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

1/20/04

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number	09/910388
Filing Date	July 20, 2001
First Named Inventor	Kunz, Lawrence
Group Art Unit	1653
Examiner Name	Unknown

Attorney Docket No: 00295.003US5

TECH CENTER 1600/2900

JUN 26 2002

RECEIVED

## US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date if Appropriate
CHK	5,385,935	01/31/1995	Tamal et al	514	535	09/07/1993
	5,393,772	02/28/1995	Yue et al	514	410	11/24/1993
	5,441,947	08/15/1995	Dodge et al	514	179	08/25/1993
	5,464,650	11/07/1995	Berg et al	427	2.30	04/26/1993
	5,478,860	12/26/1995	Wheeler et al	514	449	06/04/1993
	5,516,781	05/14/1996	Morris et al	514	291	05/12/1994
	5,519,042	05/21/1996	Morris et al	514	378	01/13/1994
	6,268,390	07/31/2001	Kunz	514	411	12/22/1999

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
	EP 0 588 518	03/23/1994		A61K	31/165	
	EP 0 622 076	11/02/1994		A61K	31/165	
	EP 0 691 130	01/10/1996		A61K	31/71	
	WO 93/09790	05/27/1993		A61K	31/70	
	WO 94/03644	02/17/1994		C12Q	1/68	
	WO 94/04164	03/03/1994		A61K	31/795	
	WO 94/04178	03/03/1994		A61K	37/02	
	WO 94/07529	04/14/1994		A61K	39/00	
	WO 94/15646	07/21/1994		A61K	48/00	
	WO 94/18345	08/18/1994		C12Q	1/68	
	WO 94/18967	09/01/1994		A61K	31/415	
	WO 94/18968	09/01/1994		A61K	31/415	
	WO 94/20096	09/15/1994		A61K	31/40	
	WO 94/20097	09/15/1994		A61K	31/40	
	WO 94/21679	09/29/1994		C07K	13/00	
	WO 94/22436	10/13/1994		A61K	31/165	
	WO 95/03036	02/02/1995		A61K	9/16	
	WO 95/03795	02/09/1995		A61K	31/335	

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GREGORY et al., "Effects of Treatment with Cyclosporine, FK 506, Rapamycin, Mycophenolic Acid, or Deoxyspergualin on Vascular Muscle Proliferation In Vivo", Transplantation Proceedings, 25, 770-771 (1993).	
		MORE et al., "A Targeted Anti-thrombotic Conjugate with Antiplatelet and Fibrinolytic Properties which Reduces in vivo Thrombus Formation", Cardiovascular Research, 27, 2200-2204 (1993).	

EXAMINER

DATE CONSIDERED


1/20/04

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)



Sheet 2 of 2

Complete if Known

Application Number	09/910388
Filing Date	July 20, 2001
First Named Inventor	Kunz, Lawrence
Group Art Unit	1653
Examiner Name	Unknown

Attorney Docket No: 00295.003US5

JUN 26 2002  
TECH CENTER 1600/2900

RECEIVED

**OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		NUNES et al., "Vitamins C and E Improve the Response to Coronary Balloon Injury in the Pig: Effect of Vascular Remodeling", <u>Circulation</u> , 88, Abstract No. 1994, I-372 (1993).	
		SPEIR et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis", <u>Science</u> , 265, 391-394 (1994).	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Form 1449\*

Atty. Docket No.: 295.003US5

Serial No. 09/910,388

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Applicant: Lawrence L. Kunz et al.

(Use several sheets if necessary)

Filing Date: July 20, 2001

Group: 1653

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>AK</i>	5,591,227	01/07/1997	Dinh et al.	623	1	04/27/95
<i>J</i>	5,599,352	02/04/1997	Dinh et al.	623	1	09/15/94
<i>J</i>	5,624,411	04/29/1997	Tuch	604	265	06/07/95
<i>J</i>	6,087,479	07/11/2000	Stamler et al.	530	363	06/02/95

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
<i>AK</i>	94/28721	12/22/1994	PCT	A01N	43/42	

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	Document
<i>AK</i>	Feelisch, M., et al., "Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and Endothelial Cells", <u>Biochemical and Biophysical Research Communications</u> , 180, 286-293 (1991).
<i>AK</i>	Garg, U.C., et al., "Nitric Oxide-Generating Vasodilators and 8-Bromo-Cyclic Guanosine Monophosphate Inhibit Mitogenesis and Proliferation of Cultured Rat Vascular Smooth Muscle Cells", <u>Journal of Clinical Investigation</u> , 83, 1774-1777 (1989).

RECEIVED  
MAR 25 2002  
TECH CENTER 1600/2900

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 1

Form 1449	Atty. Docket No.: 295.003US5	Serial No. 09/910,388
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz et al.	
	Filing Date: July 20, 2001	Group: 1653

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>AK</i>	5,837,008	11/17/1998	Berg et al.	623	1	04/27/95
<i>AK</i>	5,716,981	02/10/1998	Hunter et al.	514	449	06/07/95

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
-----------------------	-----------------	------	---------	-------	----------	-----------------------

## OTHER DOCUMENTS

**Examiner Initial	(Including Author, Title, Date, Pertinent Pages, Etc.)
	Palmaz et al., "Intravascular Stents", <u>Advances in Vascular Surgery</u> , 1, 107-135 (1993).
	Powell et al., "Suppression of the Vascular Response to Injury: The Role of Angiotensin-Converting Enzyme Inhibitors", <u>JACC</u> , 17, 137B-142B (1991).
	Schatz, "A View of Vascular Stents", <u>Circulation</u> , 79, 445-457 (1989).

RECEIVED  
JAN 29 2002  
TECH CENTER 1600/2900

Examiner <i>Anne Robinson</i>	Date Considered <i>1/26/01</i>
-------------------------------	--------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>HR</i>	3,940,422	02/24/1976	Harita et al.	260	340	01/17/74
	4,070,484	01/24/1978	Harita et al.	424	319	12/21/76
	4,093,709	06/06/1978	Sok Choi et al.	424	19	01/28/75
	4,235,988	11/25/1980	Fildes et al.	528	79	05/31/79
	4,389,330	06/21/1983	Tice et al.	427	213.36	10/06/80
	4,442,119	04/10/1984	Magarian et al.	424	274	07/26/82
	4,485,096	11/27/1984	Bell	424	95	05/26/82
	4,485,097	11/27/1984	Bell	424	95	05/25/83
	4,512,762	04/23/1985	Spears	604	21	11/23/82
	4,555,402	11/26/1985	Matsuda et al.	424	122	08/10/84
	4,577,636	03/25/1986	Spears	128	654	11/23/82
	4,675,189	06/23/1987	Kent et al.	424	490	02/08/85
	4,732,763	03/22/1988	Beck et al.	424	433	09/28/84
	4,744,981	05/17/1988	Pavanasasivam	424	85	10/14/85
	4,824,436	04/25/1989	Wolinsky	604	53	04/21/87
	4,826,672	05/02/1989	Milius et al.	424	1	06/07/85
	4,835,002	05/30/1989	Wolf et al.	426	590	07/10/87
	4,839,155	06/13/1989	Mccague	424	1	09/09/87
	4,859,585	08/22/1989	Sonnenschein et al.	435	29	04/17/86
	4,867,973	09/19/1989	Goers et al.	530	387	09/13/84
	4,879,225	11/07/1989	Morgan Jr. et al.	435	68	03/11/87
	4,879,315	11/07/1989	Magarian et al.	514	754	09/21/87
	4,897,255	01/30/1990	Fritzberg et al.	424	1	06/19/87
	4,906,452	03/06/1990	Sivam	424	10	04/28/88
	4,929,602	05/29/1990	Harker et al.	514	18	11/22/88
	4,935,415	06/19/1990	Nakano et al.	514	211	03/20/87
	4,962,091	10/09/1990	Eppstein et al.	514	2	05/23/86
	4,968,350	11/06/1990	Bindschaedler et al.	106	170	04/01/88
	4,990,538	02/05/1991	Harris et al.	514	648	08/23/89
	4,994,033	02/19/1991	Shockey et al.	604	101	05/29/89
	4,997,652	03/05/1991	Wong	424	428	05/31/89
	5,009,659	04/23/1991	Hamlin et al.	606	159	10/30/89
	5,015,578	05/14/1991	Schroeder et al.	435	119	02/20/90
	5,015,666	05/14/1991	Magarian et al.	514	754	09/22/89
	5,026,537	06/25/1991	Daddona et al.	424	1.1	05/06/89
	5,032,679	07/16/1991	Brandley et al.	536	21	08/31/89
	5,043,335	08/27/1991	Kleinschroth et al.	514	211	06/23/90
	5,047,431	09/10/1991	Schickaneder et al.	514	648	05/14/90

Examiner <i>Chap Robinson</i>	Date Considered <i>1/20/04</i>
-------------------------------	--------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>LR</i>	5,049,132	09/17/1991	Schaffer et al.	604	101	01/08/90
	5,053,033	10/01/1991	Clarke et al.	606	3	10/10/90
	5,059,166	11/22/1991	Fischell et al.	600	3	12/11/89
	5,066,789	11/19/1991	Srinivasan et al.	530	388	09/29/89
	5,073,633	12/17/1991	Schroeder et al.	540	545	11/05/90
	5,093,330	03/03/1992	Caravatti et al.	514	211	03/21/91
	5,098,903	03/24/1992	Magarian et al.	514	255	11/06/89
	5,102,402	04/07/1992	Dror et al.	604	265	01/04/91
	5,112,305	05/12/1992	Barath et al.	704	96	10/16/90
	5,114,719	05/19/1992	Sabel et al.	424	422	09/14/89
	5,116,864	05/26/1992	March et al.	514	455	04/09/91
	5,120,535	06/09/1992	Marquardt et al.	424	85.5	05/04/87
	5,140,012	08/18/1992	McGovern et al.	514	19	05/31/90
	5,166,143	11/24/1992	Ondetti et al.	514	89	06/13/91
	5,171,217	12/15/1992	March et al.	604	53	02/28/91
	5,176,617	01/05/1993	Fischell et al.	600	3	11/21/91
	5,180,366	01/19/1993	Woods	604	96	10/10/90
	5,185,260	02/09/1993	Crissman et al.	435	244	08/29/91
	5,189,046	02/23/1993	Burch et al.	514	330	08/14/90
	5,189,212	02/23/1993	Ruenitz	562	468	09/07/90
	5,192,525	03/09/1993	Yang et al.	424	11	06/28/91
	5,199,939	04/06/1993	Dake et al.	600	3	02/23/90
	5,208,019	05/05/1993	Hanson et al.	424	85	09/27/89
	5,208,238	05/04/1993	King	514	255	06/18/90
	5,213,576	05/25/1993	Abiuso et al.	604	96	06/11/91
	5,213,580	05/25/1993	Slepian et al.	623	1	03/25/92
	5,216,024	06/01/1993	Markaverich et al.	514	543	07/15/88
	5,216,126	06/01/1993	Cox et al.	530	350	06/19/91
	5,219,548	06/15/1993	Yang et al.	424	1	10/01/90
	5,221,620	06/22/1993	Purchio et al.	435	69	12/05/89
	5,226,430	07/13/1993	Spears et al.	128	898	05/24/91
	5,229,495	04/20/1993	Ichijo et al.	530	350	06/18/91
	5,232,444	08/03/1993	Just et al.	604	96	02/25/91
	5,232,911	08/03/1993	Vidal	514	12	07/23/91
	5,238,714	08/24/1993	Wallace et al.	427	213	10/02/90
	5,238,950	08/24/1993	Clader et al.	514	360	12/17/91
	5,242,397	09/07/1993	Barath et al.	604	96	01/02/92
	5,248,764	09/28/1993	Flanagan et al.	530	324	02/27/92

Examiner <i>Abel Robinson</i>	Date Considered <i>1/20/04</i>
-------------------------------	--------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>h</i>	5,254,594	10/19/1993	Niikura et al.	514	648	04/08/92
	5,260,224	11/09/1993	Stossel et al.	436	503	10/10/91
	5,268,358	12/07/1993	Fretto et al.	514	12	05/06/91
	5,268,455	12/07/1993	Cianciolo	530	404	01/23/92
	5,270,047	12/14/1993	Kauffman et al.	424	422	11/21/91
	5,280,016	01/18/1994	Conrad et al.	514	56	09/03/91
	5,280,109	01/18/1994	Miyazono et al.	530	399	01/27/92
	5,282,785	02/01/1994	Shapland et al.	604	21	10/05/92
	5,283,257	02/01/1994	Gregory et al.	514	458	07/10/92
	5,284,763	02/08/1994	Derynk et al.	435	240	03/04/92
	5,284,869	02/08/1994	Bisaccia et al.	514	455	12/17/91
	5,288,711	02/22/1994	Mitchell et al.	514	56	04/28/92
	5,288,735	02/22/1994	Trager et al.	514	363	06/15/92
	5,296,492	03/22/1994	Shiozawa et al.	514	337	06/03/92
	5,304,325	04/19/1994	Kaufman et al.	252	312	11/13/91
	5,304,541	04/19/1994	Purchio et al.	514	12	03/14/91
	5,308,622	05/03/1994	Casscells et al.	424	422	07/16/92
	5,308,862	05/03/1994	Ohlstein et al.	514	411	03/05/93
	5,314,679	05/24/1994	Lewis et al.	424	9	12/22/92
	5,316,766	05/31/1994	Baldus et al.	424	94	02/06/90
	5,324,736	06/28/1994	Magarin et al.	514	317	08/16/93
	5,326,757	07/05/1994	Demopoulos	514	167	08/18/93
	5,328,471	07/12/1994	Slepian	604	101	08/04/93
	5,332,584	07/26/1994	Scher et al.	424	408	12/09/91
	5,340,925	08/23/1994	Lioubin et al.	530	395	06/17/92
	5,346,702	09/13/1994	Na et al.	424	490	12/04/92
	5,346,897	09/13/1994	King	514	290	06/10/92
	5,346,993	09/13/1994	Miyazono et al.	530	399	07/15/93
	5,354,562	10/11/1994	Platz et al.	424	489	01/16/93
	5,354,774	10/11/1994	Deckelbaum et al.	514	455	12/24/92
	5,356,713	10/18/1994	Charmot et al.	428	407	06/01/93
	5,358,844	10/25/1994	Stossel et al.	435	2	02/18/93
	5,362,424	11/08/1994	Lee et al.	264	4.3	10/10/91
	5,362,478	11/08/1994	Desai et al.	424	9	03/26/93
	5,364,632	11/15/1994	Benita et al.	424	450	03/09/93
	5,364,843	11/15/1994	King	514	15	06/10/92
	5,380,716	01/10/1995	Conrad et al.	514	56	12/28/92
	5,393,763	02/28/1995	Black et al.	514	333	01/12/94

Examiner <i>Shope</i>	Date Considered <i>1/20/01</i>
-----------------------	--------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>HW</i>	5,395,610	03/07/1995	King	424	10	05/28/93
	5,423,885	06/13/1995	Williams	623	1	07/14/93
	5,444,164	08/22/1995	Purchio et al.	536	23.5	05/04/92
	5,453,436	09/26/1995	Ohlstein	514	411	03/17/94
	5,458,568	10/17/1995	Racchini et al.	604	19	09/17/93
	5,460,807	10/24/1995	Cardin et al.	424	78	08/19/92
	5,462,925	10/31/1995	Ogawa et al.	514	12	11/20/92
	5,468,746	11/21/1995	Casagrande et al.	514	235.5	06/21/91
	5,512,268	04/30/1996	Grinstaff et al.	424	9.322	06/06/95
	5,527,337	06/18/1996	Stack et al.	606	198	02/01/91
	5,563,146	10/08/1996	Morris et al.	514	291	05/26/95
	5,616,608	04/01/1997	Kinsella et al.	514	449	04/18/96
	5,646,160	07/08/1997	Morris et al.	514	291	05/26/95
	5,665,728	09/09/1997	Morris et al.	514	291	05/26/95
	5,733,925	03/31/1998	Kunz et al.	514	499	10/28/96
	5,776,184	07/07/1998	Tuch	623	1	10/09/96
	5,811,447	09/22/1998	Kunz, et al.	514	411	05/25/95
	5,824,048	10/20/1998	Tuch	623	1	10/09/96
	5,945,456	08/31/1999	Grainger et al.	514	651	11/06/97
	6,074,659	06/13/2000	Kunz et al.	424	423	07/10/98
	Re. 32,944	06/06/1989	Harita et al.	562	455	06/01/77
	Re. 33,403	11/23/1990	Stolle et al.	424	87	01/13/89

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
	0 260 066	03/16/1988	European	C07C	217/54	
	0 297 946	01/04/1989	European	A61K	31/40	
	0 365 863	05/02/1990	European	C07D	413/04	
	0 374 044	06/20/1990	European	C12N	15/16	
	0 411 893	02/06/1991	European	C12N	15/13	
	0 451 202	10/16/1991	European	A61K	9/70	
	0 526 102	02/03/1993	European	A61M	29/02	
	0 577 215	01/05/1993	European	A61K	9/14	
	0 606 613	07/20/1994	European	G01N	33/531	
	85/00107	01/17/1985	PCT	A61K	31/13	
	88/10259	12/29/1988	PCT	C07D	313/00	
	90/01969	03/08/1990	PCT	A61M	29/00	

Examiner *John Robinson* Date Considered *1/20/04*

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## FOREIGN PATENT DOCUMENTS

**Examiner						Translatio
No	Inventor Number	Date	Country	Class	Subclass	Yes
	90/11676	10/18/1990	PCT			
	90/12597	11/01/1990	PCT	A61K	47/48	
	90/13293	11/15/1990	PCT	A61K	31/40	
	91/15219	10/14/1991	PCT	A61K	37/00	
	91/15222	10/17/1991	PCT	A61K	37/02	
	91/17731	11/28/1991	PCT	A61F	7/12	
	92/08480	05/29/1992	PCT	A61K	37/36	
	92/11872	07/23/1992	PCT	A61K	47/48	
	92/11890	07/23/1992	PCT	A61M	25/00	
	92/11895	07/23/1992	PCT	A61K	31/00	
	92/18546	10/29/1992	PCT	C08B	37/10	
	92/19273	11/12/1992	PCT	A61K	49/02	
	92/21363	12/10/1992	PCT	A61K	37/02	
	93/07748	04/29/1993	PCT	A01N	43/16	
	93/11120	06/10/1993	PCT	C07D	263/62	
	93/17121	09/02/1993	PCT	C12P	17/02	
	93/24476	12/09/1993	PCT	C07D	305/14	
	94/08604	04/28/1994	PCT	A61K	37/00	
	94/08605	04/28/1994	PCT	A61K	37/00	
	94/15590	07/21/1994	PCT	A61K	9/51	
	94/16706	08/04/1994	PCT	A61K	31/535	
	94/17786	08/18/1994	PCT	A61K	9/16	
	94/18954	09/01/1994	PCT	A61K	9/48	
	94/19000	09/01/1994	PCT	A61K	37/02	
	94/19001	09/01/1994	PCT	A61K	37/02	
	94/19003	09/01/1994	PCT	A61K	37/02	
	94/25020	11/10/1994	PCT	A61K	31/335	

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	
	"Cytochalasins", In: <u>The Merck Index, Eleventh Edition</u> , Merck & Co., Rahway, NJ, 438-439 (1989).
	"Nolvadex Tamoxifene Citrate", <u>ICI Pharma</u> , 64033-02, Rev. L/07/92.

Examiner

Date Considered

\*Substitute Disclosure Statement (Form (PTO-1449))

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Allemann, E., et al., "Drug Loaded Poly(lactic acid) Nanoparticles Produced by a Versible Salting-out Process: Purification of an Injectable Dosage Form", <u>Eur. J. Pharm. Biopharm.</u> , <u>39</u> , 13-18 (1993).
	Anderson, et al., "Effects of Acetate Dialysate on Transforming Growth Factor B1-interleukin and B2-micoglobulin Plasma Levels", <u>Kidney International</u> , <u>40</u> , 1110-1117 (1991).
	Aschermann, M., "Restenosis after percutaneous transluminal coronary angioplasty Pathophysiology, new trends in prevention and treatment", <u>Cor Vasa</u> , <u>36</u> , 211-218 (1994).
	Assoian, et al., "Type Beta Transforming Growth Factor in Human Platelets: Release During Platelet Degranulation and Action on Vascular Smooth Muscle Cells", <u>J. Cell. Biol.</u> , <u>102</u> , 1217-1223 (1986).
	Attwood, et al., "A Light Scattering Study on Oil-in-Water Microemulsions", <u>Int'l J. Pharm.</u> , <u>52</u> , 165-171 (1989).
	Bagdade, J.D., et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition", <u>J. Clinical Endocrinology and Metabolism</u> , <u>70</u> , 1132-1135 (1990).
	Bamburg, J.R., et al., "Biological and Biochemical Actions of Trichothecene Mycotoxins", In: <u>Progress in Molecular and Subcellular Biology</u> , Vol. 8, Hahn, F.E., et al., (eds.), Springer-Verlag, New York, p. 41-110 (1983).
	Barath, et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury", <u>JACC</u> , <u>13</u> , 252A, (1989).
	Barbacid, M., et al., "Binding of [acetyl-14C]Trichodermin to the Peptidyl Transferase Center of Eukaryotic Ribosomes", <u>Euro. J. Biochem.</u> , <u>44</u> , 437-444 (1974).
	Beck, et al., "Poly(DL-lactide-co-glycolide)/norethisterone microcapsules: an injectible biodegradable contraceptive", <u>Biol. Reprod.</u> , <u>28</u> , 186-195 (1983).
	Bertelli, et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels", <u>Breast Cancer Res. and Treatment</u> , <u>12</u> , 307-310 (1988).

Examiner

*Chad Robinson*

Date Considered

1/20/04

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Bogyo, D., et al., "Cytochalasin-B-induced Immunosuppression of Murine Allogenic Anti-Tumor Response and the Effect of Recombinant Human Interleukin-2", <u>Cancer Immunol. Immunother.</u> , 32, 400-405 (1991).
	Bousquet, P.F., et al., "Effects of Cytochalasin B in Culture In Vivo on Murine Madison 109 Lung Carcinoma and on B16 Melanoma", <u>Cancer Research</u> , 50, 1431-1439 (1990).
	Bruengger, et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steriod Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs", <u>J. Urology</u> , 130, 1208-1210 (1983).
	Bruning, et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", <u>Br. J. Cancer</u> , 58, 497-499 (1988).
	Bumol, et al., "Unique Glycoprotein-proteoglycan Complex Defined by Monoclonal Antibody on Human Melanoma Cells", <u>PNAS USA</u> 79, 1245-1249 (1982).
	Butta, A., et al., "Induction of Transforming Growth Factor Beta1 in Human Breast Cancer in Vivo Following Tamoxifen Treatment", <u>Cancer Research</u> , 52, 4261-4164 (1992).
	Casscells, W., et al., "Elimination of Smooth Muscle Cells in Experimental Restenosis: Targeting of Fibroblast Growth Factor Receptors", <u>Proc. Natl. Acad. Sci. USA</u> , 89, 7159-7163 (1992).
	Chaldakov, G.N., et al., "Cyclic AMP- and Cytochalasin B-induced Arborization in Cultured Aortic Smooth Muscle Cells: Its Cytopharmacological Characterization", <u>Cell and Tissue Research</u> , 255, 434-442 (1989).
	Chander, et al., "Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer", <u>Cancer Res.</u> , 51, 5851-5858 (1991).
	Chao, et al., "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome", <u>Cytokine</u> , 3, 292-298 (1991).
	Chapman, G.D., et al., "A Bioabsorbable Stent: Initial Experimental Results", <u>Supplement III Circulation</u> , 82, Abstract No. 0283, III-72, (1990).

Examiner

*Chye Robinson*

Date Considered

1/20/04

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Clowes, A.W., et al., "Kinetics of Cellular Proliferation after Arterial Injury -- I. Smooth Muscle Growth in the Absence of Endothelium", <u>Laboratory Investigation</u> , 49, 327-333 (1983).
	Clowes, A.W., et al., "Kinetics of Cellular Proliferation after Arterial Injury -- III. Endothelium and Smooth Muscle Growth in Chronically Denuded Vessels", <u>Laboratory Investigation</u> , 54, 295-303 (1986).
	Clowes, A.W., et al., "Mechanisms of Stenosis after Arterial Injury", <u>Laboratory Investigation</u> , 49, 208-21 (1983).
	Clowes, A.W., et al., "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery", <u>Circulation Research</u> , 56, 139-145 (1985).
	Cohen, et al., "Controlled Delivery Systems for Proteins Based on Poly(lactic/glycolic acid) Microspheres", <u>Pharmaceutical Research</u> , 8, 713-720 (1991).
	Cole, R.J., et al., "The Cytochalasins", <u>In: Handbook of Toxic Fungal Metabolites</u> , Academic Press, New York, p. 264-265, 281-282 (1981).
	Cowsar, et al., "Poly(lactide-co-glycolide) Microcapsules for Controlled Release of Steroids", <u>Methods Enzymology</u> , 112, 101-116 (1985).
	Crissman, H.A., et al., "Transformed Mammalian Cells are Deficient in Kinase-Mediated Control of Progression Through the G1 Phase of the Cell Cycle", <u>Proc. Natl. Acad. Sci. USA</u> , 88, 7580-7584 (1991).
	Danielpour, "Improved Sandwich Enzyme-linked Immunosorbent Assays Transforming Growth Factor B1", <u>J. Immunol. Methods</u> , 158, 17-25 (1993).
	Danielpour, D., et al., "Evidence for Differential Regulation of TGF-Beta1 and TGF-Beta2 Expression in Vivo by Sandwich Enzyme-linked Immunosorbent Assays", <u>Annals N.Y. Acad. Sci.</u> , 593, 300-302 (1990).
	Danielpour, D., et al., "Immunodetection and Quantitation of the Two Forms of Transforming Growth Factor-Beta (TGF-Beta1 and TGF-Beta2) Secreted by Cells in Culture", <u>J. Cell. Physiol.</u> , 138, 79-86 (1989).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449\*

Atty. Docket No.: 295.003US5

Serial No. Unknown

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicant: Lawrence L. Kunz

Filing Date: Herewith

Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

Dasch, J.R., et al., "Capture Immunoassays Specific for TGF-Betal and TGF-Beta2: Use in Pharmacokinetic Studies", Annals N.Y. Acad. Sci., 593, 303-305 (1990).

Detre, K., et al., "Percutaneous Transluminal Coronary Angioplasty in 1985-1986 and 1977-1981", The New England Journal of Medicine, 318, 265-270 (1988).

Dimond, P.F., "TGF-Beta Shows Potential as Therapeutic Agent for Macular Holes", Genetic Engineering News, p. 7, 19, (1993).

Ebner, et al., "Cloning of a Type I TGF-B Receptor and Its Effect on TGF-B Binding to the Type II Receptor", Science, 260, 1344-1348 (1993).

Eldridge, J.H., et al., "Biodegradable and Biocompatible Poly(DL-Lactide-Co-Glycolide) Microspheres as an Adjuvant for Staphylococcal Enterotoxin B Toxoid Which Enhances the Level of Toxin-Neutralizing Antibodies", Infection and Immunity, 59, 2978-2986 (1991).

Epstein, S.E., et al., "Cytotoxic Effects of a Recombinant Chimeric Toxin on Rapidly Proliferating Vascular Smooth Muscle Cells", Circulation, 84, 778-787 (1991).

Fanelli, C., et al., "Restenosis Following Coronary Angioplasty", American Heart Journal, 119, 357-368 (1990).


Farhat, et al., "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium.", Br. J. Pharmacol., 107, 679-683 (1992).

Faxon, D.P., et al., "Restenosis Following Transluminal Angioplasty in Experimental Atherosclerosis", Arteriosclerosis, 4, 189-195 (1984).


Fay, M.J., et al., "Effects of Cytochalasin B on the Uptake of Ascorbic Acid and Glucose by 3T3 Fibroblasts: Mechanism of Impaired Ascorbate Transport in Diabetes", Life Sciences, 46, 619-624 (1990).

Fischer, et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis Experimental and Molecular Pathology", Exp. Mol. Pathol., 43, 288-296 (1985).

Examiner



Date Considered



\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

Forrester, J.S., et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies", <u>JACC</u> , <u>17</u> , 758-769 (1991).
Friberg, et al., "Microemulsions and Solubilization by Nonionic Surfactants", <u>Prog. Colloid and Polymer Sci.</u> , <u>56</u> , 16-20 (1975).
Fulop, T., et al., "Age-Dependent Variations of Intralysosomal Enzyme Release from Human PMN Leukocytes under Various Stimuli", <u>Immunobiol.</u> , <u>171</u> , 302-310 (1986).
Garrigues, et al., "The Melanoma Proteoglycan: Restricted Expression on Microspikes, a Specific Microdomain of the Cell Surface.", <u>J. Cell. Biol.</u> , <u>103</u> , 1699-1710 (1986).
Gasco, et al., "In Vitro Permeation of Azelaic Acid from Viscosized Microemulsions", <u>International Journal of Pharmaceutics</u> , <u>69</u> , 193-196 (1991).
Gasco, M.R., et al., "Long-acting Delivery Systems for Peptides: Reduced Plasma Testosterone Levels in Male Rats after a Single Injection", <u>Intl. J. of Pharmaceut.</u> , <u>62</u> , 119-123 (1990).
Glagov, S., et al., "Compensatory Enlargement of Human Atherosclerotic Coronary Arteries", <u>New England Journal of Medicine</u> , <u>316</u> , 1371-1375 (1987).
Goldman, et al., "Influence of Pressure on Permeability of Normal and Diseased Muscular Arteries to Horseradish Peroxidase.", <u>Atherosclerosis</u> , <u>65</u> , 215-225 (1987).
Grainger, D.J., et al., "A Large Accumulation of Non-Muscle Myosin Occurs at First Entry into M Phase in Rat Vascular Smooth-Muscle Cells.", <u>Biochemical Journal</u> , <u>277</u> , 145-151 (1991).
Grainger, D.J., et al., "Heparin Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells by Releasing Transforming Growth Factor beta-like Activity from Serum", <u>Cardiovascular Research</u> , <u>27</u> , 2238-2247 (1993).
Grainger, D.J., et al., "Hexamethylenebisacetamide Selectively Inhibits the Proliferation of Human and Rat Vascular Smooth-Muscle Cells", <u>Biochemical Journal</u> , <u>283</u> , 403-408 (1992).

Examiner

*Hope Robinson*

Date Considered

*1/20/84*

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

Atty. Docket No.: 295.003US5

Serial No. Unknown

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicant: Lawrence L. Kunz

Filing Date: Herewith

Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

Grainger, D.J., et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth-Muscle Cells in Culture by Inducing Production of Transforming Growth Factor Beta", Biochem J. 294, 109-112 (1993).

Hanke, H., et al., "Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-Weight Heparin", Circulation, 85, 1548-1556 (1992).

Harpel, et al., "Plasmin Catalysis Binding of Lipoprotein (A) to Immobilized Fibrinogen and Fibrin.", Proc. Natl. Acad. Sci. USA, 86, 3847-3851 (1989).

Heldin, et al., "Demonstration of an Antibody Against Platelet-Derived Growth Factor.", Exp. Cell. Res., 136, 255-261 (1981).

Heller, et al., "Preparation of Polyacetals by the Reaction of Divinyl Ethers and Polyols.", J. Polymer Science, Polymer Letters Edition, 18, 293-297 (1980).

Henriksson, et al., "Hormonal Regulation of Serum Lp (a) Levels.", J. Clin. Invest., 89, 1166-1171 (1992).

Hoff, H.F., et al., "Modification of Low Density Lipoprotein with 4-Hydroxynonenal Induces Uptake by Macrophages", Arteriosclerosis, 9, 538-549 (1989).

Hofmann, J., et al., "Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C", Int. J. Cancer, 42, 382-388 (1988).

Holland, J.A., et al., "Atherogenic Levels of Low-Density Lipoprotein Increase Endocytotic Activity in Cultured Human Endothelial Cells", American Journal of Pathology, 140, 551-558 (1992).

Hwang et al., "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1, and TGF-B) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture.", Exp. Cell Res., 200, 358-360 (1992).

Jarvis, B.B., et al., "Allelopathic Agents from Parthenium hysterophorus and Baccharis megapotamica", In: Chemistry of Alleopathy: Biochemical Interactions Among Plants, ACS Symposium Series No. 268, Thompson, A.C., (ed.), 149-159 (1985).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Jarvis, B.B., et al., "Macrocyclic and Other Novel Trichothecenes: Their Structure, Synthesis, and Biological Significance", <u>Acc. Chem. Res.</u> , <u>15</u> , 388-395 (1982).
	Johnson, et al., "Coronary Atherectomy: Light Microscopic and Immunochemical Study of Excised Tissues", <u>Supp. II Circulation</u> , <u>78</u> , Abstract No. 0327, page 11-82 (1988).
	Jordan, V.C., et al., "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept to Clinical Trials", <u>Hormones, Cell Biology, and Cancer: Perspectives and Potentials</u> , Alan R. Liss, Inc., 105-123 (1988).
	Jung, S.M., et al., "Platelet Cytoskeletal Protein Distributions in Two Triton-Insoluble Fractions and How They are Affected by Stimulants and Reagents that Modify Cytoskeletal Protein Interactions", <u>Thrombosis Research</u> , <u>50</u> , 775-787 (1988).
	Kambic, H., et al., "Biomaterials in Artificial Organs", <u>Chemical &amp; Engineering News</u> , <u>30</u> , 31-48, (1986).
	Kemp, P.R., et al., "The Id Gene is Activated by Serum but is Not Required for De-differentiation in Rat Vascular Smooth Muscle Cells", <u>Biochemical Journal</u> , <u>277</u> , 285-288 (1991).
	Knabbe, C., et al., "Evidence That Transforming Growth Factor beta is a Hormonally Regulated Negative Growth Factor in Human Breast Cancer Cells", <u>Cell</u> , <u>48</u> , 417-428 (1987).
	Koff, et al., "Negative Regulation of G1 in Mammalian Cells: Inhibition of Cyclin E-Dependent Kinase by TGF-B.", <u>Science</u> , <u>260</u> , 536-538 (1993).
	Kovach, J.A., et al., "Serial Intravascular Ultrasound Studies Indicate that Chronic Recoil is an Important Mechanism of Restenosis Following Transcatheter Therapy", <u>JAAC</u> , <u>21</u> , Abstract No. 835-3, p. 484A (1993).
	Lafont, A.M., et al., "Post-Angioplasty Restenosis in the Atherosclerotic Rabbit: Proliferative Response or Chronic Constriction?", <u>Circulation</u> , <u>88</u> , 66th Scientific Sessions, Abstract No. 2806, p. I-521 (1993).

Examiner <i>A. P. E. W. B. L. M.</i>	Date Considered <i>1/20/04</i>
--------------------------------------	--------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Lambert, C.R., et al., "Local Drug Delivery Catheters: Functional Comparison of Porous and Microporous Designs", <u>Coronary Artery Disease</u> , 4, 469-475 (1993).
	Lefer, "Role of Transforming Growth Factor Beta in Cardioprotection of the Ischemic-Reperfused Myocardium", <u>Growth Factors and the Cardiovascular System</u> , P. Cummins, ed., Kluwer Academic Publishers, 249-260 (1993).
	Lefer, et al., "Mechanisms of the Cardioprotective Effect of Transforming Growth Factor B1 in Feline Myocardial Ischemia and Reperfusion", <u>PNAS (USA)</u> , 90, 1018-1022 (1993).
	Lefer, A.M., et al., "Mediation of Cardioprotection by Transforming Growth Factor Beta", <u>Science</u> , 249, 61-64 (1990).
	Levy, "Drug Release from Submicronized O/W Emulsion: A New In Vitro Kinetic Evaluation Model", <u>Intl. J. Pharmaceut.</u> , 66, 29-37 (1990).
	Levy, R.J., et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants", <u>In: Biotechnology and Bioactive Polymers</u> , Proceedings of an American Chemical Society Symposium, Gebelein, C.G., (ed.), Plenum Press, New York, 259-268 (1994).
	Li, et al., "Structure and Dynamics of Microemulsions which Mimic the Lipid Phase of Low-Density Lipoproteins", <u>Biochimica et Biophysica Acta</u> , 1042, 42-50 (1990).
	Liaw, et al., "Osteopontin Promotes Vascular Cell Adhesion and Spreading and is Chemotactic for Smooth Muscle Cells in Vitro", <u>Cir. Res.</u> , 74, 214-224 (1992).
	Lin, et al., "Expression Cloning of the TGF-B Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase.", <u>Cell</u> , 68, 775-785 (1992).
	Linn, et al., "Microemulsion for Intradermal Delivery of Cetyl Alcohol and Octyl Dimethyl Paba", <u>Drug Development and Industrial Pharmacy</u> , 16, 899-920 (1990).

Examiner

*Chad Robinson*

Date Considered

1/20/04

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

Lipski, K.M., et al., "Cytochalasin B: Preparation, Analysis in Tissue Extracts, and Pharmacokinetics after Intraperitoneal Bolus Administration in Mice", <u>Analytical Biochemistry</u> , 161, 332-340 (1987).
Liu, M.D., et al., "Restenosis After Coronary Angioplasty - Potential Biologic Determinants and Role of Intimal Hyperplasia", <u>Circulation</u> , 79, 1374-87 (1989).
Love, et al., "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women.", <u>Annals of Internal Medicine</u> , 115, 860-864 (1991).
Love, et al., "Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients with Node-Negative Breast Cancer", <u>J. Natl. Cancer Ins.</u> , 82, 1327-1332 (1990).
Malcolmson, et al., "A Comparison Between Nonionic Micelles and Microemulsions as a Means of Incorporating the Poorly Water Soluble Drug Diazepam", <u>J. Pharm. Pharmacol.</u> , 42, 6P, (1990).
Manasek, F.J., et al., "The Sensitivity of Developing Cardiac Myofibrils to Cytochalasin-B", <u>Proc. Natl. Acad. Sci. USA</u> , 69, 308-213 (1972).
Mang, T.D., "Distribution to Normal and Tumor Tissues of Cytochalasin B after Intravenous Administration in Mice", Bachelor of Science Thesis, Syracuse University, New York, (1994).
Massague, "The transforming growth factor-B family", <u>Ann. Rev. Cell Biol.</u> , 6, 597-641 (1990).
McCaffrey, T.A., et al., "Transforming Growth Factor-beta Activity is Potentiated by Heparin via Dissociation of the Transforming Growth Factor-beta/alpha2-Macroglobulin Inactive Complex", <u>The Journal of Cell Biology</u> , 109, 441-448 (1989).
McCarold, et al., "Preliminary Studies on the Regulation of Secretion of Latent Transforming Growth Factor-B (TGF-B) by Endothelial Cells in Culture.", <u>Clin. Chem.</u> , 36, Abstract No. 0934, 1152, (1990).
McClellan, et al., "cDNA sequence of human apolipoprotein (a) is homologous to plasminogen", <u>Nature</u> , 330, 132-137 (1987), 132-137 (1987).

Examiner

*Hope Robinson*

Date Considered

*1/20/14*

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449\*

Atty. Docket No.: 295.003US5

Serial No. Unknown

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicant: Lawrence L. Kunz

Filing Date: Herewith

Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	McCormick, et al., "Retinoid-Tamoxifen Interaction in Mammary Cancer Chemoprevention", <u>Carcinogenesis</u> , 7, 193-196 (1986).
	McDonald, et al., "Fatal Myocardial Infarction in the Scottish Adjuvant Tamoxifen Trial.", <u>B. Med. J.</u> , 303, 435-437 (1991).
	McQuiggan, J.D., "Tissue Distribution of Cytochalasin B After Intraperitoneal Bolus and Microencapsulated Injection in Mice and its Effect on beta-N-Acetylglucosaminidase Activity in Cultured B16-BL6 Melanoma Cells", Masters' Thesis, Syracuse University, New York, 41 p., (1988).
	Merrilees, et al., "Synthesis of TGF-B1 by Vascular Endothelial Cells is Correlated with Cell Spreading.", <u>J. Vasc. Res.</u> , 29, 376-384 (1992).
	Middlebrook, J.L., et al., "Specific Association of T-2 Toxin with Mammalian Cells", <u>Biochemical Pharmacology</u> , 38, 3093-3102 (1989).
	Morisaki, et al., "Effects of transforming growth factor-B, on growth of aortic smooth muscle cells", <u>Atherosclerosis</u> , 88, 227-234 (1991).
	Nabel, "Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall", <u>Science</u> , 244, 1342-1344 (1989).
	Naito, M., et al., "Vascular Endothelial Cell Migration In Vitro: Roles of Cyclic Nucleotides, Calcium Ion and Cytoskeletal System", <u>Artery</u> , 17, 21-31 (1989).
	Nakao, J., et al., "Calcium Dependency of Aortic Smooth Muscle Cell Migration Induced by 12-L-Hydroxy-5,8,10,14-eicosatetraenoic Acid", <u>Atherosclerosis</u> , 46, 309-319 (1983).
	Nikol, S., et al., "Expression of Transforming Growth Factor Beta 1 is Increased in Human Vascular Restenosis Lesions", <u>J. Clin. Invest.</u> , 90, 1582-1592 (1992).
	O'Brien, et al., "Osteopontin mRNA and Protein are Overexpressed in Human Coronary Atherectomy Specimens: Clues to Lesion Calcification.", <u>Circulation</u> , 88, Abstract No. 3330, I-609, (1993).

Examiner

Hope Robinson

Date Considered

1/20/04

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	O'Connor-McCourt, et al., "Latent Transforming Growth Factor-B in Serum: A Specific Complex with a2-macroglobin", <u>J. Biol. Chem.</u> 262, 14090-14099, (1987).
	Ohmi, K., et al., "Effect of K252a, A protein kinase inhibitor, on the proliferation of vascular smooth muscle cells", <u>Biochemical and Biophysical Research Communications</u> , 173(3), 976-981 (1990).
	Oliveira, M.M., et al., "Isolation and Characterization of Smooth Muscle Cell Membranes", <u>Biochimica et Biophysica Acta</u> , 332, 221-232 (1974).
	Osborne, et al., "Microemulsions as Topical Drug Delivery Vehicles: In Vitro Transdermal Studies of a Model Hydrophilic Drug", <u>J. Pharm. Pharmacol.</u> , 43, 451-454 (1991).
	Osipow, "Transparent Emulsion", <u>J. Soc. Cosmetic Chemists</u> , 277-285 (1963).
	Pardee, A.B., et al., "Control of Cell Proliferation", <u>Cancer</u> , 39, 2747-2754 (1977).
	Pathak, et al., "Enhanced Stability of Physostigmine Salicylate in Submicron o/w Emulsion", <u>International Journal of Pharmaceutics</u> , 65, 169-175 (1990).
	Podzimek, et al., "O/W Microemulsions", <u>J. Dispersion Science and Technology</u> , 1, 341-359 (1980).
	Popma, J.J., et al., "Factors Influencing Restenosis after Coronary Angioplasty", <u>The American Journal of Medicine</u> , 88, 1-16N--1-24N, (1990).
	Post, M.J., et al., "Restenosis is Partly Due to Intimal Hyperplasia and Partly to Remodeling of the Injured Arterial Wall", <u>European Heart Journal</u> , Abstract No. P1164, p. 201, (1993).
	Post, M.J., et al., "Which Part of the Angiographic Diameter Reduction After Balloon Dilation is Due to Intimal Hyperplasia?", <u>JACC</u> , 21, Abstract No. 851-95, I-36A, (1993).
	Pouton, C.W., "Self-Emulsifying Drug Delivery Systems: Assessment of the Efficiency of Emulsification", <u>International Journal of Pharmaceutics</u> , 27, 335-348, (1985).

Examiner

*Chloe Robinson*

Date Considered

1/28/04

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

	Rauterberg, J., et al., "Collagens in Atherosclerotic Vessel Wall Lesions", <u>Current Topics in Pathology</u> , 87, 163-192 (1993).
	Reid, V.C., et al., "Fragmentation of DNA in P388D, Macrophages Exposed to Oxidized Low-Density Lipoprotein", <u>FEBS Letters</u> , 332, 218-220 (1993).
	Ross, R., "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", <u>Nature</u> , 362, 801-809 (1993).
	Ross, R., et al., "Chronic Inflammation, PDGF, TGF $\beta$ , and Smooth Muscle Proliferation", <u>Molecular Mechanisms of Vascular Diseases</u> , Abstract No. G006, 96 (1991).
	Sagitani, et al., "Microemulsion Systems with a Nonionic Cosurfactant", <u>J. Dispersion Science and Technology</u> , 1 (2), 151-164 (1980).
	Sanders, et al., "Controlled Release of a Luteinizing Hormone-Releasing Hormone Analogue from Poly(D,L-lactide-co-glycolide) Microspheres.", <u>J. Pharmaceutical Science</u> , 73, 1294-1297 (1984).
	Schlingemann, et al., "Expression of the High Molecular Weight Moleculoma-Associated Antigen by Pericytes During Angiogenesis in Tumors and in Healing Wounds.", <u>Amer. J. Pathology</u> , 136, 1393-1405 (1990).
	Schneiderman, et al., "Increased Type 1 Plasminogen Activator Inhibitor Gene Expression in Atherosclerotic Human Arteries.", <u>PNAS (USA)</u> , 89, 6998-7002 (1992).
	Schwartz, R.S., et al., "Restenosis After Balloon Angioplasty -- A Practical Proliferative Model in Porcine Coronary Arteries", <u>Circulation</u> , 82, 2190-2200 (1990).
	Schwartz, R.S., et al., "The Restenosis Paradigm Revisited: An Alternative Proposal for Cellular Mechanisms", <u>JACC</u> , 20, 1284-1293, (1992).
	Schwartz, S.M., et al., "Maintenance of Integrity in Aortic Endothelium", <u>Federation Proceedings</u> , 39, 2618-2625 (1980).
	Shanahan, C.M., et al., "Isolation of Gene Markers of Differentiated and Proliferating Vascular Smooth Muscle Cells", <u>Circulation Research</u> , 73, 193-204 (1993).

Examiner <i>John E. Roberts</i>	Date Considered <i>1/20/04</i>
---------------------------------	--------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

	Shewmon, D.A., et al., "Tamoxifen Lowers Lp(a) in Males with Heart Disease", <u>Supplement I Circulation</u> , <u>86</u> , 1345 (1992).
	Shoji, et al., "Enhancement of Anti-Inflammatory Effects of Biphenyllylactic Acid by its Incorporation into Lipid Microspheres.", <u>J. Pharm. Pharmacol</u> , <u>38</u> , 118-121 (1986).
	Simpson, J.B., et al., "Percutaneous Coronary Atherectomy", <u>Circulation</u> , <u>78</u> , 61st Scientific Session, Abstract No. 0326, p. II-82, (1988).
	Singh, et al., "Phylogenetic Analysis of Platelet-derived Growth Factor by Radio-Receptor Assay.", <u>J. Cell Biol.</u> , <u>95</u> , 667-671 (1982).
	Snow, A.D., et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells", <u>American Journal of Pathology</u> , <u>137</u> , 313-330 (1990).
	Steele, P.M., et al., "Balloon Angioplasty -- Nature History of the Pathophysiological Response to Injury in a Pig Model", <u>Circulation Research</u> , <u>57</u> , 105-112 (1985).
	Streuli, C.H., et al., "Extracellular Matrix Regulates Expression of the TGF-Beta 1 Gene", <u>J. Cell Biol.</u> , <u>120</u> , 253-260 (1993).
	Suckling, K.E., "Emerging Strategies for the Treatment of Atherosclerosis as Seen from the Patent Literature", <u>Biochemical Society Transactions</u> , <u>21</u> , 660-662 (1993).
	Tamm, C., "The Antibiotic Complex of the Verrucarins and Roridins", <u>Fortschr. Chem. Org. Naturst.</u> , <u>31</u> , 61-117 (1973).
	Tice, et al., "Biodegradable controlled-release parental systems", <u>Pharmaceutical Technology</u> , 26-35 (1984).
	Topol, E.J., et al., "The Restenosis "Antitheory"", <u>Mayo Clin. Proc.</u> , <u>68</u> , 88-90 (1993).
	Vanhoutte, "Hypercholesterolaemia, Atherosclerosis and Release of Endothelium-Derived Relaxing Factor by Aggregating Platelets", <u>Eur. Heart J.</u> , <u>12</u> , Suppl. E, 25-32 (1991).

Examiner

*Hope Robinson*

Date Considered

*1/20/04*

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Vargas, et al., "Oestradiol Inhibits Smooth Muscle Cell Proliferation of Pig Coronary Artery.", <u>Br. J. Pharmacol.</u> , 109, 612-617 (1993).
	Vijayagopal, P., et al., "Human Monocyte-Derived Macrophages Bind Low-Density-Lipoprotein-Proteoglycan Complexes by a Receptor Different from the Low-Density-Lipoprotein Receptor", <u>Biochemical Journal</u> , 289, 837-844 (1993).
	Vijayagopal, P., et al., "Lipoprotein-Proteoglycan Complexes Induce Continued Cholesteryl Ester Accumulation in Foam Cells from Rabbit Atherosclerotic Lesions", <u>J. Clin. Invest.</u> , 91, 1011-1018 (1993).
	Voisard, R., et al., "The in-vitro Effect of Antineoplastic Agents on Proliferative Activity and Cytoskeletal Components of Plaque-derived Smooth-muscle Cells from Human Coronary Arteries", <u>Coronary Artery Disease</u> , 4, 935-942 (1993).
	Wakefield, et al., "Latent Transforming Growth Factor-B from Human Platelets: A High Molecular Weight Complex Containing Precursor Sequences.", <u>J. Biol. Chem.</u> , 263, 7646-7654 (1988).
	Wakefield, et al., "Recombinant Latent Transforming Growth Factor-B, has a Longer Plasma Half-Life in Rats than Active Transforming Growth Factor-B, and a Different Tissue Distribution.", <u>J. Clin. Invest.</u> , 86, 1976-1984 (1990).
	Weissberg, P.L., et al., "Approaches to the Development of Selective Inhibitors of Vascular Smooth Muscle Cell Proliferation", <u>Cardiovascular Research</u> , 27, 1191-1198 (1993).
	Weissberg, P.L., et al., "Effects of TGF-Beta on Vascular Smooth Muscle Cell Growth", In: <u>Growth Factors and the Cardiovascular System</u> , Cummins, P., (ed.), Kluwer Academic Publishers, 189-205 (1993).
	Weissberg, P.L., et al., "The Endothelin Peptides ET-1, ET-2, ET-3 and Sarafotoxin S6b are Co-mitogenic with Platelet-Derived Growth Factor for Vascular Smooth Muscle Cells", <u>Atherosclerosis</u> , 85, 257-262 (1990).
	Wight, "Proteoglycans Structure and Function", <u>Cell Biol. of Extracellular Matrix</u> , Second Edition, E.D. Hay, Ed., Plenum Press, New York, 45-78 (1991).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*	Atty. Docket No.: 295.003US5	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Lawrence L. Kunz	
	Filing Date: Herewith	Group: Unknown

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Wight, et al., "Cell Biology of Arterial Proteoglycans.", <u>Arteriosclerosis</u> , 9, 1-20 (1989).
	Wight, et al., "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation.", <u>Current Opinion in Cell Biol.</u> , 4, 793-801 (1992).
	Wilensky, R.L., et al., "Direct Intraarterial Wall Injection of Microparticles via a Catheter: A Potential Drug Delivery Strategy Following Angioplasty", <u>American Heart Journal</u> , 122, 1136-1140 (1991).
	Wolinsky, H., et al., "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery.", <u>JACC</u> , 15, 475-481 (1990).
	Zuckerman, et al., "Cytokine Regulation of Macrophage apo E. Secretion: Opposing Effects of GM-CSF and TGF-B.", <u>Atherosclerosis</u> , 96, 203-214 (1992).
	Zuckerman, et al., "Exogenous Glucocorticoids Increase Macrophage Secretion of apo E by Cholesterol Independent Pathways.", <u>Atherosclerosis</u> , 103, 43-54 (1993).

Examiner

*Ann Robinson*

Date Considered

*1/20/04*

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.